A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Biomarkers of AZD3839 Including an Open-label Food Effect Group in Healthy Male and Female Volunteers of Non-childbearing Potential.
Phase of Trial: Phase I
Latest Information Update: 01 Jan 2014
At a glance
- Drugs AZD 3839 (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Adverse reactions
- 05 Apr 2012 Actual patient number added 72 according to ClinicalTrials.gov.
- 05 Apr 2012 Actual end date (June 2011) added as reported by ClinicalTrials.gov.
- 05 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.